Abstract

Biomarkers have emerged as valuable tools in asthma management, offering insights into disease severity, predicting exacerbations, and guiding personalized treatment strategies. This mini-review explores the role of biomarkers in unlocking better asthma control. Key biomarkers like Fractional exhaled nitric oxide (FeNO), blood eosinophil counts, and periostin have shown promise in aiding asthma diagnosis, predicting exacerbations, and monitoring treatment response. These biomarkers enable clinicians to tailor treatment plans to individual patient needs, optimizing efficacy while minimizing side effects. Despite their potential, challenges such as variability in biomarker levels, lack of standardization, and cost implications exist. Future research should focus on validating and standardizing biomarkers, exploring new potential indicators, and integrating them into comprehensive asthma management algorithms. Collaboration between researchers, clinicians, and industry stakeholders is essential to overcome these challenges and advance the field. In conclusion, biomarkers hold immense promise for reshaping asthma management, moving towards personalized, targeted treatment approaches, and ultimately improving the quality of life for asthma patients worldwide.